Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results

January 30, 2025

Hovione and Zerion collaborate to market the technology program Dispersome®

March 1, 2022

Hippocratic AI Secures $53M Funding from General Catalyst, Memorial Hermann, UHS, a16z and others

March 22, 2024

Must Read

What an Autonomous Clinical Trial Might Look Like by 2030

August 8, 2026

Takeda’s Orzeyful Approved as First Orexin Agonist for Narcolepsy Type 1

August 8, 2026

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

August 6, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Supernus and Indivior Agree to Create CNS-Focused Company in All-Stock Merger

Hinge Health to Buy Out Cylinder Health in a Deal Worth Over $100M

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

What an Autonomous Clinical Trial Might Look Like by 2030

From Data-Rich to Insight-Rich: Pharma’s Next Transformation

The New Competitive Advantage in Biopharma Isn’t Science Alone

Why Protocol Complexity Continues to Threaten Trial Success

Tag: sleep disorders

Takeda’s Orzeyful Approved as First Orexin Agonist for Narcolepsy Type 1

Editor Picks

Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results

Hovione and Zerion collaborate to market the technology program Dispersome®

Hippocratic AI Secures $53M Funding from General Catalyst, Memorial Hermann, UHS, a16z and others

Must Read

What an Autonomous Clinical Trial Might Look Like by 2030

Takeda’s Orzeyful Approved as First Orexin Agonist for Narcolepsy Type 1

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Hot Topics

About Us

Follow Us